Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 5
1986 3
1987 9
1988 3
1989 6
1990 12
1991 12
1992 9
1993 15
1994 12
1995 16
1996 14
1997 17
1998 15
1999 25
2000 10
2001 21
2002 22
2003 16
2004 27
2005 22
2006 19
2007 14
2008 13
2009 9
2010 10
2011 12
2012 10
2013 18
2014 9
2015 26
2016 10
2017 14
2018 16
2019 11
2020 9
2021 6
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

473 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Tannock IF, et al. N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Free article. Clinical Trial.
BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. ...The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the gr …
BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prost …
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.
FINDINGS: 755 men were allocated to treatment groups (377 mitoxantrone, 378 cabazitaxel) and were included in the intention-to-treat analysis. ...Median progression-free survival was 2.8 months (95% CI 2.4-3.0) in the cabazitaxel group and 1.4 months (1.4-1.7) in the mi …
FINDINGS: 755 men were allocated to treatment groups (377 mitoxantrone, 378 cabazitaxel) and were included in the intention-to-treat …
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Berthold DR, et al. J Clin Oncol. 2008 Jan 10;26(2):242-5. doi: 10.1200/JCO.2007.12.4008. J Clin Oncol. 2008. PMID: 18182665 Clinical Trial.
PURPOSE: The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). ...
PURPOSE: The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with …
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Martinelli Boneschi F, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD002127. doi: 10.1002/14651858.CD002127.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728638 Free article. Review.
BACKGROUND: This is an updated Cochrane review of the previous published version.Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. ...
BACKGROUND: This is an updated Cochrane review of the previous published version.Mitoxantrone (MX) has been shown to be moderately ef …
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Martinelli Boneschi F, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002127. doi: 10.1002/14651858.CD002127.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235298 Updated. Review.
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. ...
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity …
Mitoxantrone-related acute leukemia in MS: an open or closed book?
Chan A, Lo-Coco F. Chan A, et al. Neurology. 2013 Apr 16;80(16):1529-33. doi: 10.1212/WNL.0b013e31828cf891. Neurology. 2013. PMID: 23589639 Review.
Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), especially in Europe, its benefit-risk profile remains controversial. ...
Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), e …
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Jaramillo S, Le Cornet L, Kratzmann M, Krisam J, Görner M, Hänel M, Röllig C, Wass M, Scholl S, Ringhoffer M, Reichart A, Steffen B, Kayser S, Mikesch JH, Schaefer-Eckart K, Schubert J, Geer T, Martin S, Kieser M, Sauer T, Kriegsmann K, Hundemer M, Serve H, Bornhäuser M, Müller-Tidow C, Schlenk RF. Jaramillo S, et al. Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x. Trials. 2023. PMID: 37715270 Free PMC article. Clinical Trial.
Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the patients achieving a CR. ...METHODS: In this multicenter, upfront randomized …
Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen) …
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Ellis R, Brown S, Boggild M. Ellis R, et al. Mult Scler. 2015 Apr;21(5):642-5. doi: 10.1177/1352458514541508. Epub 2014 Jul 10. Mult Scler. 2015. PMID: 25013152 Review.
Therapy-related acute leukaemia (TRAL) is a significant concern, when considering treatment with mitoxantrone for multiple sclerosis (MS). We re-evaluated the literature, identifying all case reports and series of > 50 patients reporting TRAL cases in MS. ...We found th …
Therapy-related acute leukaemia (TRAL) is a significant concern, when considering treatment with mitoxantrone for multiple sclerosis …
High-dose mitoxantrone in acute leukaemia: New York Medical College experience.
Feldman EJ. Feldman EJ. Eur J Cancer Care (Engl). 1997 Dec;6(4 Suppl):27-32. doi: 10.1111/j.1365-2354.1997.tb00322.x. Eur J Cancer Care (Engl). 1997. PMID: 9460340 Review.
Based on promising preclinical data, a progressive series of evaluations of the use of high-dose mitoxantrone-based chemotherapy was initiated in acute leukaemia patients. ...Patients receiving high-dose mitoxantrone did not experience increased morbidity or mortali …
Based on promising preclinical data, a progressive series of evaluations of the use of high-dose mitoxantrone-based chemotherapy was …
Addition of mitoxantrone and prednisone to ADT.
Gourd E. Gourd E. Lancet Oncol. 2018 Jul;19(7):e336. doi: 10.1016/S1470-2045(18)30406-6. Epub 2018 May 24. Lancet Oncol. 2018. PMID: 29804903 Clinical Trial. No abstract available.
473 results

Searches related to "mitoxantrone"